Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.

Tucci M, Caffo O, Buttigliero C, Cavaliere C, D'aniello C, Di Maio M, Kinspergher S, Maines F, Rizzo M, Rossetti S, Veccia A, Scagliotti GV, Facchini G.

Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7. Review.

PMID:
30738364
2.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
3.

Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Francini E, Yip S, Ahmed S, Li H, Ardolino L, Evan CP, Kaymakcalan M, Shaw GK, Kantoff PW, Taplin ME, Alimohamed NS, Joshua AM, Heng DYC, Sweeney CJ.

Clin Genitourin Cancer. 2018 Apr;16(2):130-134. doi: 10.1016/j.clgc.2017.12.012. Epub 2017 Dec 27.

4.

Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.

Tassinari D, Cherubini C, Roudnas B, Tamburini E, Drudi F, Bianchi E, Fantini M, Montanari F, Sartori S.

Rev Recent Clin Trials. 2018;13(3):226-237. doi: 10.2174/1574887113666180404120540.

PMID:
29623850
5.

Sequencing of agents in castration-resistant prostate cancer.

Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G.

Lancet Oncol. 2015 Jun;16(6):e279-92. doi: 10.1016/S1470-2045(15)70033-1. Epub 2015 May 27. Review.

PMID:
26065613
6.

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F.

World J Urol. 2016 May;34(5):617-24. doi: 10.1007/s00345-015-1687-0. Epub 2015 Sep 15. Review.

PMID:
26373956
7.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
8.

Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.

Mizokami A, Kadono Y, Kitagawa Y, Izumi K, Konaka H.

Int J Urol. 2017 Aug;24(8):566-572. doi: 10.1111/iju.13372. Epub 2017 Jun 3. Review.

9.
10.

Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.

Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ.

Eur Urol. 2017 Jul;72(1):10-13. doi: 10.1016/j.eururo.2017.03.007. Epub 2017 Mar 15.

PMID:
28314611
11.

Challenges in the sequencing of therapies for the management of metastatic castration-resistant prostate cancer.

Parente P, Parnis F, Gurney H.

Asia Pac J Clin Oncol. 2014 Sep;10(3):205-15. doi: 10.1111/ajco.12193. Epub 2014 Apr 3. Review.

PMID:
24750803
12.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
13.

New treatment options for patients with metastatic prostate cancer.

Snoeks LL, Ogilvie AC, van Haarst EP, Siegert CE.

Neth J Med. 2013 Jul-Aug;71(6):290-4. Review.

14.

Perspectives on treatment of metastatic castration-resistant prostate cancer.

Merseburger AS, Bellmunt J, Jenkins C, Parker C, Fitzpatrick JM; European Treatment Practices Group.

Oncologist. 2013;18(5):558-67. doi: 10.1634/theoncologist.2012-0478. Epub 2013 May 13. Review. Erratum in: Oncologist. 2013;18(8):971. Oncologist. 2013;18(6):775.

15.

The third line of treatment for metastatic prostate cancer patients: Option or strategy?

Roviello G, Petrioli R, Laera L, Francini E.

Crit Rev Oncol Hematol. 2015 Sep;95(3):265-71. doi: 10.1016/j.critrevonc.2015.04.010. Epub 2015 May 21. Review.

PMID:
26052050
16.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
17.

Treatment sequencing in metastatic castrate-resistant prostate cancer.

Sartor O, Gillessen S.

Asian J Androl. 2014 May-Jun;16(3):426-31. doi: 10.4103/1008-682X.126378. Review.

18.

[Treatment of metastatic castration-resistant prostate cancer].

Caffo O.

Recenti Prog Med. 2015 Jan;106(1):35-9. doi: 10.1701/1740.18958. Italian.

PMID:
25621779
19.

Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis.

Yamada Y, Matsubara N, Tabata KI, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H, Yano A, Kawakami S.

BMC Res Notes. 2016 Oct 18;9(1):471.

20.

Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.

Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.

Clin Genitourin Cancer. 2015 Aug;13(4):392-399. doi: 10.1016/j.clgc.2015.01.004. Epub 2015 Jan 24.

PMID:
25708161

Supplemental Content

Support Center